{"organizations": [], "uuid": "6bcfb2192ef667d4b75338d903aaace89cc67543", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-to-close-b/brief-five-prime-therapeutics-to-close-bladder-cancer-cohort-of-its-phase-1-fpa144-001-trial-idUSFWN1RN0OX", "country": "US", "domain_rank": 408, "title": "BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.328, "site_type": "news", "published": "2018-04-11T00:58:00.000+03:00", "replies_count": 0, "uuid": "6bcfb2192ef667d4b75338d903aaace89cc67543"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-to-close-b/brief-five-prime-therapeutics-to-close-bladder-cancer-cohort-of-its-phase-1-fpa144-001-trial-idUSFWN1RN0OX", "ord_in_thread": 0, "title": "BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - five prime therapeutics inc", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 4:58 PM / Updated 25 minutes ago BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial Reuters Staff 1 Min Read \nApril 10 (Reuters) - Five Prime Therapeutics Inc: \n* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN \n* SAYS TO CONTINUE TREATING BLADDER CANCER PATIENTS CURRENTLY ON STUDY BUT WILL NOT ENROLL ADDITIONAL PATIENTS IN COHORT-SEC FILING Source text: ( bit.ly/2HnAIag ) Further company coverage:", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "http://bit.ly/2HnAIag"], "published": "2018-04-11T00:58:00.000+03:00", "crawled": "2018-04-10T20:01:02.000+03:00", "highlightTitle": ""}